Updated - ago
Moderna's MRNA perp rose 1.25% to $219.41 with $14.8M in 24-hour notional volume, supported by investor focus on its recent Analyst Day where management raised its full-year 2026 revenue growth guidance to 15% to 25% and outlined upcoming oncology and respiratory product milestones.1
Moderna, Inc. is an American biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company develops and manufactures therapeutics and vaccines based on synthetic messenger RNA technology. Its platform delivers nucleoside-modified messenger RNA inside lipid nanoparticles to instruct human cells to produce targeted proteins that generate protective immune responses. Moderna achieved global distribution with its primary COVID-19 vaccine, Spikevax, which received emergency authorization in 2020 and full regulatory approval in 2022. The company expanded its commercial portfolio with mRESVIA, an approved messenger RNA vaccine targeting respiratory syncytial virus in older adults. Its research pipeline includes clinical candidates for various cancers and infectious pathogens such as influenza, cytomegalovirus, and HIV. Moderna operates development and manufacturing facilities in Norwood, Massachusetts, and trades on the Nasdaq exchange under the ticker symbol MRNA.